The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo

Molecular Cancer Therapeutics

Volumn 1, Issue 2, 2001, Pages 85-94

  Rusnak, David W ^a   Lackey, Karen ^a   Affleck, Karen ^b   Wood, Edgar R ^a   Alligood, Krystal J ^a   Rhodes, Nelson ^a   Keith, Barry R ^a   Murray, Doris M ^a   Glennon, Kimberly ^a   Knight, W Blaine ^a   Mullin, Robert J ^a   Gilmer, Tona M ^a  

^a GLAXOSMITHKLINE   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FURAN DERIVATIVE; N (3 CHLORO 4 ((3 FLUOROBENZYL)OXY)PHENYL 6 (5 ((METHYLSULFONYL)ETHYL)AMINOMETHYL) 2 FURYL) 4 QUINAZOLINAMINE; N-(3-CHLORO-4-((3-FLUOROBENZYL)OXY)PHENYL-6-(5-((METHYLSULFONYL)ETHYL)AMINOMETHYL)-2-FURYL)-4-QUINAZOLINAMINE; QUINAZOLINE DERIVATIVE;

ANIMAL; APOPTOSIS; ARTICLE; CELL CULTURE; CELL CYCLE; CELL DIVISION; COMPARATIVE STUDY; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; EXPERIMENTAL NEOPLASM; FEMALE; FIBROBLAST; HUMAN; METABOLISM; MOUSE; MOUSE MUTANT; NEWBORN; NUDE MOUSE; PATHOLOGY; PHOSPHORYLATION; SERODIAGNOSIS; SIGNAL TRANSDUCTION; SKIN; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL DIVISION; ENZYME INHIBITORS; EPIDERMAL GROWTH FACTOR; FEMALE; FIBROBLASTS; FURANS; HUMANS; INFANT, NEWBORN; MICE; MICE, NUDE; MICE, SCID; NEOPLASMS, EXPERIMENTAL; PHOSPHORYLATION; PRECIPITIN TESTS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; SKIN; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0035553174     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Krasilnikov, M. A. Phosphatidylinositol-3 kinase dependent pathways: the role in control of cell growth, survival, and malignant transformation. Biochemistry (Mosc). 65: 59-67, 2000.
2. Moyer, J. D., Barbacci, E. G., Iwata, K. K., Arnold, L., Boman, B., Cunningham, A., DiOrio, C., Doty, J., Morin, M. J., Moyer, M. P., Neveu, M., Pollack, V. A., Pustilnik, L. R., Reynolds, M. M., Sloan, D., Theleman, A., and Miller, P. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res., 57: 4838-4848, 1997. (Pubitemid 27468992)
3. Ciardiello, F., Caputo, R., Bianco, R., Damiano, V., Pomatico, G., Placido, S. D., Bianco, A. R., and Tortora, G. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin. Cancer Res., 6: 2053-2063, 2000. (Pubitemid 30305105)
4. Traxler, P. Tyrosine kinase inhibitors in cancer treatment (part II). Expert Opinion on Therapeutic Patents, 8: 1599-1625, 1998. (Pubitemid 28546567)
5. Swaisland, H., Laight, A., Stafford, L., Jones, H., Morris, C., Dane, A., and Yates, R. Pharmacokinetics and tolerability of the orally active selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in healthy volunteers. Clin. Pharmacol., 40: 297-306, 2001. (Pubitemid 32458155)
6. Baselga, J., and Averbuch, S. D. ZD1839 ("Iressa") as an anticancer agent. Drugs, 60: 33-42, 2000.
7. Pollack, V. A., Savage, D. M., Baker, D. A., Tsaparikos, K. E., Sloan, D. E., Moyer, J. D., Barbacci, E. G., Pustilnik, L. R., Smolarek, T. A., Davis, J. A., Vaidya, M. P., Arnold, L. D., Doty, J. L., Iwata, K. K., and Morin, M. J. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J. Pharmacol. Exp. Ther., 291: 739-748, 1999. (Pubitemid 29503548)
8. Smaill, J. B., Rewcastle, G. W., Loo, J. A., Greis, K. D., Chan, O. H., Reyner, E. L., Lipka, E., Showalter, H. D. H., Vincent, P. W., Elliott, W. L., and Denny, W. A. Tyrosine kinase inhibitors. 17 irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions. J. Med. Chem., 43: 1380-1397, 2000. (Pubitemid 30212579)
9. Cockerill, S., Stubberfield, C., Stables, J., Carter, M., Guntrip, S., Smith, K., McKeown, S., Shaw, R., Topley, P., Thomsen, L., Affleck, K., Jowett, A., Hayes, D., Willson, M., Woollard, P., and Spalding, D. Indzolylamino quinazolines and pyridopyrimidines as inhibitors of EGFr and c-erbB-2. Bioorg. Med. Chem. Lett., 11: 1401-1405, 2001. (Pubitemid 32510830)
10. Rusnak, D. W., Affleck, K., Cockerill, S. G., Stubberfield, C., Harris, R., Page, M., Smith, K. J., Guntrip, S. B., Carter, M. C., Shaw, R. J., Jowett, A., Stables, J., Topley, P., Wood, E. R., Brignola, P. S., Kadwell, S. H., Reep, B. R., Mullin, R. J., Alligood, K. J., Keith, B. R., Crosby, R. M., Murray, D. M., Knight, W. B., Gilmer, T. M., and Lackey, K. The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer. Cancer Res., 61: 7196-7203, 2001. (Pubitemid 32946515)
11. Carter, M. C., Cockerill, G. S., Guntrip, S. B., Lackey, K. E., and Smith, K. J. Bicyclic heteroaromatic compounds [quinazolinamines and analogs] useful as protein tyrosine kinase inhibitors. PCT Int. Appl., WO9935146, Glaxo Wellcome, 1999.
12. Arnold, L., and Schnur, R. Alkynyl and azido-substituted 4-anilinoquinazoline derivatives are potent inhibitors of the erbB family of oncogenic and proto-oncogenic protein tryosine kinase(s), useful for treating hyper-proliferative disorders. US Patent 5,747,498. Pfizer, Inc., 1998.
13. Gibson, K. H. Quinazoline Derivatives. US Patent 5,770,599. Zeneca Limited, 1998.
14. McDonald, O. B., Chen, W-J., Ellis, B., Hoffman, C., Overton, L., Rink, M., Smith, A., Marshall, C. J., and Wood, E. R. A scintillation proximity assay for the Raf/MEK/ERK kinase cascade: high-throughput screening and identification of selective enzyme inhibitors. Anal. Biochem., 268: 318-329, 1999. (Pubitemid 29147147)
15. Harris, R. A., Eichholtz, T. J., Hiles, I. D., Page, M. J., and O'Hare, M. J. New model of erbB-2 over-expression in human mammary luminal epithelial cells. Int. J. Cancer, 80: 477-484, 1999. (Pubitemid 29019639)
16. Woodburn, J. R. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol. Ther., 82: 241-250, 1999. (Pubitemid 29255919)
17. Modjtahedi, H., Affleck, K., Stubberfield, C., and Dean, C. EGFR blockade by tyrosine kinase inhibitor or monoclonal antibody inhibits growth, directs terminal differentiation and induces apoptosis in the human squamous cell carcinoma HN5. Int. J. Oncol., 13: 335-342, 1998. (Pubitemid 28329223)
18. Haigler, H., Ash, J., Singer, S., and Cohen, S. Visualization by fluorescence of the binding and internalization of epidermal growth factor in human carcinoma cells A-431. Proc. Natl. Acad. Sci. USA, 75: 3317-3321, 1978. (Pubitemid 8389718)
19. Pasleau, F., Grooteclaes, M., and Gol-Winkler, R. Expression of the c-erbB2 gene in the BT474 human mammary tumor cell line: measurement of c-erbB2 mRNA half-life. Oncogene, 8: 849-854, 1993. (Pubitemid 23087415)
20. Batra, J. K., Kasprzyk, P. G., Bird, R. E., Pastan, I., and King, C. R. Recombinant anti-erbB2 immunotoxins containing Pseudomonas exotoxin. Proc. Natl. Acad. Sci. USA, 89: 5867-5871, 1992.
21. Tagliabue, E., Centis, F., Campiglio, M., Mastroianni, A., Martignone, S., Pellegrini, R., Casalini, P., Lanzi, C., Menard, S., and Colnaghi, M. I. Selection of monoclonal antibodies which induce internalization and phosphorylation of p185HER2 and growth inhibition of cells with HER2/neu gene amplification. Int. J. Cancer, 47: 933-937, 1991.
22. Aguilar, Z., Akita, R. W., Finn, R. S., Ramos, B. L., Pegram, M. D., Kabbinavar, F. F., Pietras, R. J., Pisacane, P., Sliwkowski, M. X., and Slamon, D. J. Biological effects of heregulin/neu differentiation factor on normal and malignant human breast and ovarian epithelial cells. Oncogene, 18: 6050-6062, 1999. (Pubitemid 29535017)
23. Jannot, C. B., Beerli, R. R., Mason, S., Gullick, W. J., and Hynes, N. E. Intracellular expression of a single-chain antibody directed to the EGFR leads to growth inhibition of tumor cells. Oncogene, 13: 275-282, 1996. (Pubitemid 26334859)
24. Datta, S. R., Brunet, A., and Greenberg, M. E. Cellular survival: a play in three Akts. Genes Dev., 13: 2905-2927, 1999.
25. Okano, J-I., Gaslightwall, I., Birnbaum, M. J., Rustgi, A. K., and Nakagawa, H. Akt/Protein Kinase B isoforms are differentially regulated by epidermal growth factor stimulation. J. Biol. Chem., 275: 30934-30942, 2000.
26. Zhou, B. P., Hu, M. C-T., Miller, S. A., Yu, Z., Xia, W., Lin, S-Y., and Hung, M-C. HER-2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NF-κB pathway. J. Biol. Chem., 275: 8027-8031, 2000. (Pubitemid 30159714)
27. Kip1-Cdk2 complex formation: receptor overexpression does not determine growth dependency. Mol. Cell. Biol., 20: 3210-3223, 2000.
28. Baselga, J., Norton, L., Albanell, J., Kim, Y. M., and Mendelsohn, J. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res., 58: 2825-2831, 1998. (Pubitemid 28311914)
29. Sirotnak, F. M., Zakowski, M. F., Miller, V. A., Scher, H. I., and Kris, M. G. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin. Cancer Res., 6: 4885-4892, 2000. (Pubitemid 32110433)
30. Nelson, J. M., and Fry, D. W. Akt, MAPK (ERK1/2), and p38 act in concert to promote apoptosis in response to ErbB receptor family inhibition. J. Biol. Chem., 276: 14842-14847, 2001.
31. Huang, P., and Oliff, A. Signaling pathways in apoptosis as potential targets for cancer therapy. Trends Cell Biol., 11: 342-348, 2001.
32. Busse, D., Doughty, R. S., Ramsey, T. T., Russell, W. E., Price, J. O., Flanagan, W. M., Shawver, L. K., and Arteaga, C. L. Reversible G1 arrest induced by inhibition of the epidermal growth factor receptor tyrosine kinase requires up-regulation of p27KIP1independent of MAPK activity. J. Biol. Chem., 275: 6987-6995, 2000. (Pubitemid 30146243)
33. Fan, Z., and Mendelsohn, J. Therapeutic application of anti-growth factor receptor antibodies. Curr. Opin. Oncol., 10: 67-73, 1998. (Pubitemid 28039244)
34. HER2monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol. Cell. Biol., 9: 1165-1172, 1989.
35. Zhang, L., Lau, Y-K., Xi, L., Hong, R-L., Kim, D. S., Chen, C-F., Hortobagyi, G. N., Chang, C-J., and Hung, M-C. Tyrosine kinase inhibitors, emodin and its derivative, repress Her-2/neu-induced cellular transformation and metastasis-associated properties. Oncogene, 16: 2855-2863, 1998. (Pubitemid 28383270)
36. Roh, H., Pippin, J., and Drebin, J. A. Down-regulation of HER2/neu expression induces apoptosis in human cancer cells that overexpress HER2/neu. Cancer Res., 60: 560-565, 2000. (Pubitemid 30094551)
37. Hsieh, S. S., Malerczyk, C., Aigner, A., and Czubayko, F. ErbB-2 expression is rate-limiting for epidermal growth factor-mediated stimulation of ovarian cancer cell proliferation. Int. J. Cancer, 86: 644-651, 2000. (Pubitemid 30249874)
38. Bowman, T., Garcia, R., Turkson, J., and Jove, R. STATs in oncogenesis. Oncogene, 19: 2474-2488, 2000. (Pubitemid 30339203)
39. Hynes, N. E., Horsch, K., Olayioye, M. A., and Badache, A. The ErbB receptor tyrosine family as signal integrators. Endocrine-Related Cancer, 8: 151-159, 2001. (Pubitemid 32947637)
40. Olayioye, M. A., Neve, R. M., Lane, H. A., and Hynes, N. E. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J., 19: 3159-3167, 2000. (Pubitemid 30428195)
41. Bera, T. K., Viner, J., Brinkmann, E., and Pastan, I. Pharmacokinetics and antitumor activity of a bivalent disulfide-stabilized Fv immunotoxin with improved antigen binding to erbB2. Cancer Res., 59: 4018-4022, 1999. (Pubitemid 29393571)